Andre the Giant: A Clinical Before-and-After Analysis of Acromegaly and Its Visible Progression

Who Was Andre the Giant and Why Does His Case Matter Clinically?

Andre René Roussimoff was a French professional wrestler and actor whose body told the story of one of the most visually documented cases of untreated acromegaly in the 20th century. He was not simply "a big man." His skeletal and soft-tissue changes followed the exact pattern that endocrinologists now use to teach the natural history of GH excess. Because he was photographed continuously from adolescence through middle age, his images form a rare longitudinal record.

Modern acromegaly affects an estimated 40 to 60 cases per million people, with a mean diagnostic delay of 6 to 10 years from symptom onset [1]. Andre's case was never formally diagnosed or treated during his lifetime. That omission gives clinicians and researchers an unintentional "untreated control" to examine.

Why Acromegaly Goes Undetected

The Endocrine Society's 2014 clinical practice guideline on acromegaly notes that "the diagnosis is often delayed because the physical changes are subtle and occur gradually over many years" [2]. Andre grew up in rural France with limited medical access, and his size was initially celebrated rather than investigated.

Gigantism vs. Acromegaly: The Distinction That Applies to Andre

When GH excess begins before the epiphyseal growth plates close, the result is gigantism: linear height far exceeding population norms. After plate fusion, ongoing GH excess causes acromegaly: soft-tissue swelling, periosteal bone apposition, and visceral enlargement without significant additional height gain [3]. Andre's trajectory fits both phases sequentially.

Phase 1: Early Childhood to Adolescence (1946, Early 1960s)

Andre was reportedly already 6 ft 3 in tall by age 12. Photographs from this period, though sparse, show a proportionally large but not yet dysmorphic child. His face retains normal proportions. His hands are large but symmetric. This is the gigantism phase: excess GH stimulating longitudinal bone growth through insulin-like growth factor 1 (IGF-1) acting on open epiphyseal plates [4].

The Role of IGF-1 in Childhood Overgrowth

GH does not act directly on growth plates for the most part. It stimulates hepatic production of IGF-1, which then drives chondrocyte proliferation. A child with a GH-secreting pituitary adenoma can generate IGF-1 levels two to three times the age-adjusted upper limit of normal. The NEJM review by Melmed (2006) documented that pituitary GH adenomas account for over 95% of acromegaly cases [3].

Genetic Predisposition Considerations

Andre's father was reported to be of normal stature; his mother was described as shorter than average. No family history of multiple endocrine neoplasia type 1 (MEN1) or AIP mutation has been documented. Sporadic GH-secreting adenomas, the most common presentation, require no hereditary basis [5].

Phase 2: Late Adolescence to Peak Career (Early 1960s, Late 1970s)

This is the phase most richly documented in photographs. By his early 20s, Andre had entered professional wrestling and was being photographed weekly. Comparing images from 1965 to 1978 reveals a clear acromegalic progression.

Facial Changes: The Clinical Checklist

Clinicians use a standard list of craniofacial signs to screen for acromegaly. Photographs of Andre from this period show:

• Prognathism (jaw protrusion) worsening between ages 19 and 28
• Frontal bossing becoming more pronounced by the early 1970s
• Widening of the nasal bridge
• Enlargement of the supraorbital ridges
• Lip and tongue enlargement, consistent with soft-tissue acral changes

These changes correspond precisely to the acromegaly phenotype described in the Journal of Clinical Endocrinology and Metabolism's 2019 consensus update on acromegaly diagnosis [6].

Hand and Foot Progression

Andre's ring size and shoe size increased progressively through his 30s, consistent with periosteal bone apposition and soft-tissue expansion. His reported US shoe size of 22 translates to a foot length of approximately 38 cm, roughly 10 cm beyond the 99th percentile for adult males. In clinical practice, a patient reporting a sustained increase in ring size or shoe size beyond age 25 triggers an IGF-1 screen [2].

Voice Change

Several contemporaries noted that Andre's voice deepened unusually and that he developed sleep-disordered breathing in his late 20s. Upper airway soft-tissue enlargement, including the tongue, soft palate, and subglottic tissues, occurs in 60 to 80% of acromegaly patients and is a leading cause of obstructive sleep apnea in this population [7].

Phase 3: The 1980s. Visible Deterioration and Functional Decline

By the early 1980s, photographs and film appearances show a qualitatively different Andre. The 1987 film "The Princess Bride" provides high-resolution footage that allows frame-by-frame clinical observation.

Gait and Articular Changes

Andre moved with increasing difficulty through his late 30s. Acromegaly accelerates osteoarthritis through two mechanisms: direct GH/IGF-1-driven cartilage hypertrophy followed by degradation, and the mechanical load imposed by excessive body mass [8]. A 2021 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=4,936 pooled patients) found that arthropathy was present in 72% of acromegaly cases at diagnosis, with severity correlating with disease duration [8].

Cardiovascular Remodeling

Acromegalic cardiomyopathy is a distinct entity. GH and IGF-1 receptors are expressed on cardiomyocytes, and chronic excess produces biventricular hypertrophy, diastolic dysfunction, and, over time, systolic failure [9]. The European Journal of Endocrinology reports that cardiac disease is the leading cause of death in untreated acromegaly, accounting for approximately 60% of excess mortality [9].

Andre's face in 1980s photographs shows pronounced periorbital and malar soft-tissue thickening. His neck circumference appears markedly increased compared to images from the 1960s. Both findings align with the fluid retention and soft-tissue proliferation that accompany chronic GH excess.

Alcohol Intake as a Confounding Variable

Andre was publicly and extensively documented consuming extraordinary quantities of alcohol, with biographical accounts citing consumption of 100 or more beers in single sittings on multiple occasions. Chronic heavy alcohol use independently causes cardiomyopathy, peripheral neuropathy, and hepatic dysfunction. In Andre's case, separating alcohol-related from acromegaly-related organ damage is impossible retrospectively. Both processes were almost certainly additive.

Phase 4: Final Years and Cause of Death (1990 to 1993)

By 1990, Andre had undergone spinal surgery and was visibly debilitated. Photographs from his final two years show extreme soft-tissue edema, pronounced facial coarsening, and apparent respiratory distress. He died on January 27, 1993, at age 46, from congestive heart failure while in Paris for his father's funeral.

Life Expectancy in Untreated Acromegaly

A landmark meta-analysis by Dekkers et al. (2008) in the Journal of Clinical Endocrinology and Metabolism found that patients with acromegaly have a standardized mortality ratio of approximately 1.72 (95% CI 1.62 to 1.83), meaning 72% excess mortality compared to age-matched controls [10]. That figure applies to populations that had at least some access to treatment. Andre had none. His death at 46 is consistent with, and probably at the severe end of, the natural history of untreated GH-secreting adenoma with cardiovascular and articular complications.

What Octreotide Might Have Changed

The FDA approved octreotide (Sandostatin) in 1988, just five years before Andre's death [11]. Somatostatin analogue therapy reduces GH levels to below 2.5 ng/mL and normalizes IGF-1 in approximately 55 to 65% of patients, with corresponding reductions in soft-tissue swelling, sleep apnea severity, and cardiac hypertrophy [12]. Had Andre been diagnosed and treated with octreotide 120 mg LAR monthly starting in 1988, his articular and cardiac trajectory might have been meaningfully altered. He would have been 42 at the time of approval.

Modern Diagnostic Criteria: How Andre Would Be Evaluated Today

A contemporary patient presenting with Andre's phenotype would undergo a structured diagnostic pathway. The Endocrine Society's 2014 guideline and the 2019 consensus update define this as follows [2][6]:

Step 1: IGF-1 Screening

A single fasting IGF-1 level, compared against age- and sex-adjusted normative ranges, serves as the primary screen. Sensitivity exceeds 97% for active acromegaly [2]. A value above the age-adjusted upper limit of normal triggers confirmatory testing.

Step 2: Oral Glucose Tolerance Test (OGTT) with GH Measurement

75 g oral glucose is administered. In healthy adults, GH suppresses to below 0.4 ng/mL (using modern ultrasensitive assays). In acromegaly, GH fails to suppress or paradoxically rises [6]. This is the gold-standard confirmatory test.

Step 3: MRI of the Pituitary

Gadolinium-enhanced MRI of the sella turcica identifies the adenoma. Macroadenomas (diameter 10 mm or larger) are present in approximately 75% of acromegaly cases at diagnosis [3]. Andre's tumor, had it been imaged, would almost certainly have been a macroadenoma given his height and the apparent duration of disease.

Step 4: Complication Screening

Confirmed acromegaly triggers screening for sleep apnea (polysomnography), colonoscopy (acromegaly carries 2 to 3x elevated colorectal polyp risk), cardiac echocardiography, and joint assessment [2].

Photographic Before-and-After: A Stage-by-Stage Clinical Summary

Reviewing available historical photographs across the four phases described above produces a clinical picture that is consistent, progressive, and diagnostically unambiguous by modern standards.

| Age Range | Key Visible Changes | Correlating Pathophysiology | |---|---|---| | <13 years | Extreme linear growth, large but proportionate features | GH excess on open epiphyses; gigantism phase | | 13-22 years | Early prognathism, large hands, accelerating height | Plate closure; transition to acromegaly phenotype | | 22-35 years | Frontal bossing, jaw protrusion, skin thickening, voice change | Periosteal apposition, soft-tissue proliferation | | 35-43 years | Gait deterioration, edema, respiratory difficulty, extreme weight | Arthropathy, cardiomyopathy, sleep apnea | | 43-46 years | Severe functional decline, visible fluid overload | End-stage cardiac failure |

The progression visible in photographs matches the natural history described in the Melmed 2020 comprehensive review of acromegaly in the New England Journal of Medicine [13].

What Andre's Case Teaches Modern Endocrinology

Andre the Giant represents what the literature now calls "diagnostic delay with catastrophic outcome." His case is not unique in mechanism, only in its extraordinary visibility and documentation. The average acromegaly patient still waits 6 to 10 years for diagnosis today [1].

The Diagnostic Delay Problem Has Not Been Solved

A 2020 systematic review published in Pituitary (N=15 studies, 3,737 patients) found a mean diagnostic delay of 7.7 years from first symptom to confirmed diagnosis [1]. The primary barriers identified were: symptom attribution to normal aging or constitutional factors, low physician suspicion in non-specialist settings, and the gradual nature of physical change.

Screening Opportunities Missed in Andre's Era

In the 1960s and 1970s, no validated IGF-1 assay existed for clinical use. GH radioimmunoassay was only becoming available in the early 1970s. MRI did not exist until the 1980s. The diagnostic tools that would have confirmed Andre's condition before age 25 were simply not available to him, or not available in the settings where he received care.

Modern Athletes and Performers With Unusual Growth Patterns

Andre's case argues for a low threshold for IGF-1 screening in any individual presenting with height above 6 ft 6 in in combination with progressive acral enlargement, deepening voice, or sleep-disordered breathing. The Endocrine Society explicitly endorses this approach: "Patients with a newly diagnosed pituitary mass, patients with typical clinical manifestations of acromegaly, and patients with sleep apnea, type 2 diabetes, debilitating arthritis, carpal tunnel syndrome, or hyperhidrosis should be tested for acromegaly" [2].